Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    24158787 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention: Drug: Everolimus plus Exemestane
2 Active, not recruiting
Has Results
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane;   Drug: Placebo, Exemestane
3 Recruiting Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Conditions: Breast Cancer Recurrent;   HER2/Neu-negative Carcinoma of Breast;   Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Everolimus;   Drug: Exemestane;   Other: Patient questionaires

Indicates status has not been verified in more than two years